File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial

TitleEmpagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial
Authors
KeywordsCardiac MRI
Diabetes
Empagliflozin
Left atrial function
Issue Date28-Aug-2024
PublisherBioMed Central
Citation
Cardiovascular Diabetology, 2024, v. 23, n. 1 How to Cite?
Abstract

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated reduction in heart failure outcomes in patients with type 2 diabetes mellitus, although the exact mechanism of benefit remains unclear. Alteration in left atrial (LA) function due to chronic pressure or volume overload is a hallmark of heart failure.

Objective: To evaluate the effect of the SGLT2 inhibitor empagliflozin on LA volume and function.

Methods: 90 patients with coronary artery disease and type 2 diabetes (T2DM) were randomized to empagliflozin (n = 44) or placebo (n = 46), and underwent cardiac magnetic resonance (CMR) imaging at baseline and after 6 months. The main outcome was change in LA volume; LA function, including active and passive components, was also measured by a blinded reader.

Results: At baseline, there was no significant difference in LA volumes between the empagliflozin (indexed maximum LA volume 26.4 ± 8.4mL/m2, minimum LA volume 11.1 ± 5.7mL/m2) and placebo (indexed maximum LA volume 28.7 ± 8.2mL/m2, minimum LA volume 12.6 ± 5.0mL/m2) groups. After 6 months, changes in LA volumes did not differ with adjusted difference (empagliflozin minus placebo): 0.99 mL/m2 (95% CI: -1.7 to 3.7 mL/m2; p = 0.47) for indexed maximum LA volume, and 0.87 mL/m2 (95% CI: -0.9 to 2.6 mL/m2; p = 0.32) for indexed minimum LA volume. Changes in total LA emptying fraction were also similar, with between-group adjusted mean difference - 0.01 (95% CI: -0.05 to 0.03, p = 0.59).

Conclusion: SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease. (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes [EMPA-HEART]; NCT02998970).


Persistent Identifierhttp://hdl.handle.net/10722/348760
ISSN
2023 Impact Factor: 8.5
2023 SCImago Journal Rankings: 2.621

 

DC FieldValueLanguage
dc.contributor.authorPourafkari, Marina-
dc.contributor.authorConnelly, Kim A-
dc.contributor.authorVerma, Subodh-
dc.contributor.authorMazer, C David-
dc.contributor.authorTeoh, Hwee-
dc.contributor.authorQuan, Adrian-
dc.contributor.authorGoodman, Shaun G-
dc.contributor.authorRai, Archana-
dc.contributor.authorNg, Ming Yen-
dc.contributor.authorDeva, Djeven P-
dc.contributor.authorTriverio, Piero-
dc.contributor.authorJiminez-Juan, Laura-
dc.contributor.authorYan, Andrew T-
dc.contributor.authorGe, Yin-
dc.date.accessioned2024-10-15T00:30:39Z-
dc.date.available2024-10-15T00:30:39Z-
dc.date.issued2024-08-28-
dc.identifier.citationCardiovascular Diabetology, 2024, v. 23, n. 1-
dc.identifier.issn1475-2840-
dc.identifier.urihttp://hdl.handle.net/10722/348760-
dc.description.abstract<p><strong>Background: </strong>Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated reduction in heart failure outcomes in patients with type 2 diabetes mellitus, although the exact mechanism of benefit remains unclear. Alteration in left atrial (LA) function due to chronic pressure or volume overload is a hallmark of heart failure.</p><p><strong>Objective: </strong>To evaluate the effect of the SGLT2 inhibitor empagliflozin on LA volume and function.</p><p><strong>Methods: </strong>90 patients with coronary artery disease and type 2 diabetes (T2DM) were randomized to empagliflozin (n = 44) or placebo (n = 46), and underwent cardiac magnetic resonance (CMR) imaging at baseline and after 6 months. The main outcome was change in LA volume; LA function, including active and passive components, was also measured by a blinded reader.</p><p><strong>Results: </strong>At baseline, there was no significant difference in LA volumes between the empagliflozin (indexed maximum LA volume 26.4 ± 8.4mL/m2, minimum LA volume 11.1 ± 5.7mL/m2) and placebo (indexed maximum LA volume 28.7 ± 8.2mL/m2, minimum LA volume 12.6 ± 5.0mL/m2) groups. After 6 months, changes in LA volumes did not differ with adjusted difference (empagliflozin minus placebo): 0.99 mL/m2 (95% CI: -1.7 to 3.7 mL/m2; p = 0.47) for indexed maximum LA volume, and 0.87 mL/m2 (95% CI: -0.9 to 2.6 mL/m2; p = 0.32) for indexed minimum LA volume. Changes in total LA emptying fraction were also similar, with between-group adjusted mean difference - 0.01 (95% CI: -0.05 to 0.03, p = 0.59).</p><p><strong>Conclusion: </strong>SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease. (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes [EMPA-HEART]; <a href="http://clinicaltrials.gov/show/NCT02998970" title="See in ClinicalTrials.gov">NCT02998970</a>).<br></p>-
dc.languageeng-
dc.publisherBioMed Central-
dc.relation.ispartofCardiovascular Diabetology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCardiac MRI-
dc.subjectDiabetes-
dc.subjectEmpagliflozin-
dc.subjectLeft atrial function-
dc.titleEmpagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial-
dc.typeArticle-
dc.identifier.doi10.1186/s12933-024-02344-6-
dc.identifier.scopuseid_2-s2.0-85202742108-
dc.identifier.volume23-
dc.identifier.issue1-
dc.identifier.eissn1475-2840-
dc.identifier.issnl1475-2840-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats